SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01074398

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

ERCC1 Expression as a Predictor of Progression Free and Overall Survival in Patients With Epithelial Ovarian Cancer Treated on GOG Protocols 0172 and 0182

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

NCT01074398 Fallopian Tube Cancer Ovarian Cancer Peritoneal Cavity Cancer
MeSH:Ovarian Neoplasms Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms
HPO:Fallopian tube carcinoma Ovarian neoplasm

5 Interventions

Name: gene expression analysis

Type: Genetic

Name: polymorphism analysis

Type: Genetic

Name: protein expression analysis

Type: Genetic

Name: immunohistochemistry staining method

Type: Other

Name: laboratory biomarker analysis

Type: Other

Primary Outcomes

Measure: Association between ERCC1 tumor expression and progression-free and overall survival

Secondary Outcomes

Measure: Association between ERCC1 polymorphisms and ERCC1 tumor expression

There is one SNP


1 C8092A

Secondary - To correlate ERCC1 single-nucleotide polymorphisms (C8092A and codon 118) with ERCC1 tumor expression. --- C8092A ---

HPO Nodes